AcelRx Pharmaceuticals

AcelRx Pharmaceuticals EBIT per Employee

Delisted

The EBIT per Employee of AcelRx Pharmaceuticals (ACRX) as of Oct 27, 2026 is -1.41 M USD. In the previous year, EBIT per Employee was -3.05 M USD — a change of -53.90% (higher).

EBIT per Employee

-1.41 MUSD

YoY

-53.90%

Last updated:

EBIT per Employee of AcelRx Pharmaceuticals is 2023 -1.41 M USD. EBIT per Employee of AcelRx Pharmaceuticals was 2022 -3.05 M USD. It decreases by -53.90% higher compared to the previous year.

The AcelRx Pharmaceuticals EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2016
-2.66 M USD
Jan 1, 2017
-3.22 M USD
Jan 1, 2018
-2.98 M USD
Jan 1, 2019
-4.52 M USD
Jan 1, 2020
-3.41 M USD
Jan 1, 2021
-3.00 M USD
Jan 1, 2022
-3.05 M USD
Jan 1, 2023
-1.41 M USD
The AcelRx Pharmaceuticals EBIT per Employee history
YEAREBIT per EmployeeYoY
-1.41 MUSD-53.90%
-3.05 MUSD+1.86%
-3.00 MUSD-12.20%
-3.41 MUSD-24.43%
-4.52 MUSD+51.72%
-2.98 MUSD-7.64%
-3.22 MUSD+21.04%
-2.66 MUSD+60.15%
-1.66 MUSD-47.00%
-3.14 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AcelRx Pharmaceuticals Stock analysis

What does AcelRx Pharmaceuticals do? AcelRx Pharmaceuticals Inc. is a California-based company specializing in the manufacturing of pain relief medications. The company was founded in 2005 and has since become an innovator in the development of pain medications. AcelRx's business model involves selling its patented products to hospitals and other healthcare facilities, and it is currently expanding into the global market. The company focuses on developing pain medications for emergency medicine and palliative care, with a particular emphasis on delivering medications through sprays or injections for fast-acting relief. AcelRx offers products such as Zalviso, a pain reliever based on Fentanyl nasal sprays used for post-operative pain, and Dsuvia, a sublingual tablet containing the active ingredient Sufentanil for severe pain. The FDA has approved Dsuvia as safe and effective. AcelRx has also entered partnerships with other pharmaceutical companies, such as Grünenthal and Chinese company R-Pharm, to bring its products to the international market. The company is committed to investing in research and development for innovative pain relief solutions, including a new research program targeting the development of medications for neuropathic pain. AcelRx Pharmaceuticals is a positive example of how modern pharmaceuticals can improve healthcare and quality of life. The company has demonstrated its potential through dedication and continuous research and development, and it is likely to make even greater contributions in the future. AcelRx Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AcelRx Pharmaceuticals stock

EBIT per Employee of AcelRx Pharmaceuticals is -1.41 M USD in 2023.

EBIT per Employee of AcelRx Pharmaceuticals changed from -3.05 M USD to -1.41 M USD, representing a -53.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee AcelRx Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's AcelRx Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — AcelRx Pharmaceuticals

All Key Metrics — AcelRx Pharmaceuticals